Project Grant R01CA304577
Award Date 7/1/26
Completion Date 6/30/31
Dollars Obligated $622K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Columbus, OH 43210, USA
Similar Awards
- Federal Grant Award Summary The Ohio State University received a $384,524 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) on June 17, 2026, with completion scheduled for May 31, 2028. The award supports preclinical research and development of a novel immunotherapeutic platform utilizing targeted prodrug cytokines for metastatic breast cancer treatment. The research deliverables include in vitro and in vivo investigations of...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Ohio State University a $449,222 Project Grant effective August 20, 2025, through July 31, 2030, under the Cancer Treatment Research program (CFDA 93.395). This award funds research to elucidate the cellular and molecular mechanisms by which PD-1H (Programmed Death-1 Homolog, also known as VISTA) mediates immune suppression in acute myeloid leukemia (AML) and to evaluate its potential as a therapeutic target. The...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Ohio State University a Project Grant totaling $192,564 under the Cancer Research Manpower program (CFDA 93.398) effective September 1, 2025, through August 31, 2028. This award supports the development of chimeric antigen receptor (CAR) modified natural killer (NK) cell-based immunotherapy for the treatment of pediatric solid tumors. The research aims to advance NK cell engineering as a safer and more effective...
- Federal Grant Award Summary The National Cancer Institute awarded The Ohio State University a Project Grant of $394,695 under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) on June 17, 2026, with a completion date of May 31, 2028. This award supports development and validation of computational approaches to identify and characterize tumor-infiltrating lymphocytes (TILs) and tumor-associated macrophages (TAMs) in breast cancer tissue samples. The project aims to overcome...
- Federal Grant Award Summary The Ohio State University received a $390,906 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective April 1, 2026 through March 31, 2027. This research initiative, titled "Decoding Dural Nociceptors as Drivers of Immune Suppression in Glioblastoma," investigates the role of pain-sensing sensory neurons (nociceptors) in regulating the immunosuppressive tumor microenvironment...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded The Ohio State University $463,692 under the Cancer Biology Research program (CFDA 93.396) for a five-year project (June 1, 2026 – May 31, 2031) focused on comprehensive structural and dynamic characterization of human K-RAS oncoprotein. The project delivers fundamental research services aimed at understanding K-RAS interactions with binding partners and small-molecule ligands in both normal and oncogenic mutant...
- Federal Project Grant Award Summary The National Cancer Institute awarded The Ohio State University a Project Grant of $157,500 under the Cancer Cause and Prevention Research program (CFDA 93.393) on July 15, 2025, with completion scheduled for June 30, 2027. This award supports research investigating the roles of the TIP60 chromatin remodeling complex in DNA double-strand break (DSB) repair mechanisms. The research focuses on understanding how the TIP60 complex, particularly through its KAT5...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded The Ohio State University a $188,351 Project Grant under the Cancer Research Manpower program (CFDA 93.398) on September 3, 2025, with a completion date of August 31, 2028. This award supports research and career development activities focused on mutation-specific pan-KRAS (Kirsten rat sarcoma viral oncogene homolog) inhibitor signaling responses and anti-tumor effects. The project involves comprehensive genetic,...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $733,864 to the Beckman Research Institute of the City of Hope under the Cancer Biology Research program (CFDA 93.396) to identify and characterize stimulatory immune checkpoints that regulate macrophage-mediated programmed cell removal (PRCR) in tumor immunosurveillance. The five-year project, initiated June 1, 2026, and extending through May 31, 2031, will employ high-throughput CRISPR-based screening approaches to...
- Federal Grant Award Summary The University of Toledo received a $153,000 Project Grant from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396), effective August 1, 2025 through July 31, 2027. This award supports fundamental research aimed at optimizing the "knocksideways" technique to visualize and analyze interactions between protein subcomplexes, specifically focusing on the MAD1:MAD2 complex and its role in the spindle assembly checkpoint. The...